• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

Contemporary Pediatrics week in review: sNDA acceptance for roflumilast, pz-cel Priority Review, and more


Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Image credit:Contemporary Pediatrics

Image credit:Contemporary Pediatrics

Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, November 27 to Friday, December 1, 2023), and click on each link to read and watch anything you may have missed.

1.) FDA accepts sNDA for roflumilast cream 0.15% to treat atopic dermatitis

The FDA has accepted a supplemental New Drug Application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in children aged 6 years and up.

Click here for the full article.

2.) Lawrence Eichenfield, MD, reacts to accepted sNDA for roflumilast cream 0.15%

In this Contemporary Pediatrics® interview, Lawrence Eichenfield, MD, professor of dermatology and pediatrics, vice chair, Department of Dermatology, chief, Pediatric and Adolescent Dermatology, University of California, San Diego, and Rady Children’s Hospital, San Diego, reacts to the FDA's acceptance of a supplemental New Drug Application (sNDA) for roflumilast cream 0.15% (Arcutis Biotherapeutics) to treat atopic dermatitis (AD) in patients aged 6 years and older.

Click here for the video interview.

3.) Pz-cel granted FDA Priority Review to treat recessive dystrophic epidermolysis bullosa

The FDA granted Priority Review to pz-cel following a phase 1/2 and a pivotal phase 3 study in which the treatment for recessive dystrophic epidermolysis bullosa (RDEB) demonstrated wound healing and pain reduction.

Click here for the full article.

4.) 2022-2023 influenza season classified as high severity

The 2022-2023 influenza season was the fourth season to be classified as high severity since the 2009 influenza A(H1N1) pandemic.

Click here for the full article.

5.) Addressing vaccine hesitancy among guardians

Ravi Jhaveri, MD, shares approaches to addressing common concerns among parents and guardians regarding the flu vaccine for children.

Click here for the full video interview.

Related Videos
Deborah Persaud, MD
Ari Brown, MD, FAAP | Pediatrician and CEO of 411 Pediatrics; author, baby411 book series; chief medical advisor, Kabrita USA.
Steven Selbst, MD
© 2024 MJH Life Sciences

All rights reserved.